Nicotine replacement therapy products comprising synthetic nicotine
US10610526B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Dec 30, 2016 |
| Grant date | Apr 7, 2020 |
| Priority date | — |
| Expiry date | Dec 30, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61M11/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A composition suitable for use in nicotine replacement therapy products includes a nicotine product that includes a synthetic nicotine that is substantially free of one or more contaminants and/or impurities normally associated with tobacco-derived nicotine. For example, the synthetic nicotine is substantially free of one or more of nicotine-1′-N-oxide, nicotyrine, nornicotyrine, 2′,3-bipyridyl, cotinine, anabasine, and/or anatabine. The composition further comprises one or more pharmaceutically acceptable excipients, additives and/or carriers. The nicotine replacement therapy products may include any number of such products, including transdermal nicotine delivery patches, nicotine gums, synthetic chewing tobacco, synthetic snuff, and synthetic strips (e.g., dissolvable synthetic tobacco). Additionally, a method of treating nicotine addiction includes administering a nicotine replacement composition, e.g., via a nicotine replacement therapy product, to a user.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.